- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Instrumentarium ships to China
Medko Medical, the project sales unit of Instrumentarium, has cut a deal to provide medical equipment to the health bureaus of three Chinese provinces. Equipment deliveries to 13 municipal hospitals operating under China's local health bureaus will begin
Medko Medical, the project sales unit of Instrumentarium, has cut a deal to provide medical equipment to the health bureaus of three Chinese provinces. Equipment deliveries to 13 municipal hospitals operating under China's local health bureaus will begin in early fall. The projects, valued at about $7.4 million, will include x-ray as well as anesthesia equipment and monitors and infant-care products. Meanwhile, Instrumentarium's status as an independent OEM continues to hang in the balance, as European regulators sift through issues involved with GE's bid to purchase the Finnish company. Earlier this month, the European Commission issued preliminary findings on the proposed acquisition, reflecting current discussions in a document entitled the "Statement of Objections." The Wall Street Journal reported that regulators have narrowed their scrutiny of the purchase to the issue of how much power the combined entities would have over patient-monitoring devices. Industry pundits are now speculating that GE may need to make some concessions to win approval of the deal, including divestment of some parts of Instrumentarium, according to the WSJ.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
